In this single-center cohort study of 124 subjects, patients with CHD post-PCI were tested for CYP2C19 gene polymorphisms and divided into two groups: normal and hyperbolic types and abnormal metabolic (including intermediate and slow metabolic). The gene discussed is CYP2C19; the disease is coronary artery disorder.